<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cortical Neurons in Corticobasal Degeneration</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:4042028](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4042028)</td>
</tr>
</table>
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Cortical Neurons in Corticobasal Degeneration</th>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:4042028](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_4042028)</td>
</tr>
</table>
Cortical Neurons in Corticobasal Degeneration## OverviewCorticobasal degeneration (CBD) is a 4-repeat (4R) tauopathy defined pathologically by asymmetric cortical neuronal loss, astrocytic plaques (the hallmark CBD lesion), ballooned achromatic neurons, and dense cortical tau thread pathology[@dickson2002]. Cortical degeneration is the distinguishing feature that separates CBD from its sister tauopathy Progressive Supranuclear Palsy (PSP), where subcortical and brainstem pathology predominates[^2]. The asymmetric destruction of perirolandic cortex — spanning the primary motor cortex (M1), premotor areas, supplementary motor area (SMA), and primary somatosensory cortex — produces the signature clinical phenotype of corticobasal syndrome (CBS): asymmetric limb apraxia, cortical sensory loss, alien limb phenomenon, and cortical myoclonus[^3].## Neuroanatomy: Cortical Regions Affected### Primary Motor Cortex (M1, Brodmann Area 4)The precentral gyrus is one of the most severely affected regions in CBD[@dickson2002]:- Betz cells: Giant layer V pyramidal neurons (50-100 μm soma diameter) that give rise to the corticospinal tract. These neurons show prominent tau inclusions, ballooning, and progressive degeneration, producing upper motor neuron signs and weakness- Layer III pyramidal neurons: Corticocortical projection neurons connecting M1 to premotor and supplementary motor areas; their loss disrupts inter-areal coordination of movement planning- Laminar pattern: Neuronal loss is most severe in layers III and V, with relative preservation of layers II and IV[^4]### Premotor and Supplementary Motor Area (BA6)- SMA proper: Critical for self-initiated movements and bimanual coordination. SMA degeneration produces the hallmark motor initiation deficit and gait ignition failure- Pre-SMA: Involved in motor planning and sequence learning; its loss contributes to ideomotor apraxia- Lateral premotor cortex: Impaired externally cued movements### Posterior Parietal Cortex (BA5, BA7, BA39, BA40)Parietal cortex degeneration underlies the cortical sensory features of CBS[^5]:- Superior parietal lobule (BA5/7): Mediates visuospatial processing and sensory-motor integration; its loss produces visuospatial disorientation and dressing apraxia- Inferior parietal lobule: Damage to the supramarginal (BA40) and angular (BA39) gyri impairs gestural comprehension and contributes to ideational apraxia- Dorsal stream disruption: CBD preferentially affects the dorsal visual stream ("where/how" pathway), producing optic ataxia and spatial neglect### Frontal Association Cortex (BA9, BA10, BA46)Prefrontal degeneration explains the cognitive and behavioural features[^6]:- Dorsolateral prefrontal cortex: Executive dysfunction — impaired planning, working memory, cognitive flexibility- Orbitofrontal cortex: Behavioural disinhibition, impulsivity, or alternatively apathy- Anterior cingulate cortex: Reduced motivation and error monitoring; contributes to akinetic mutism in advanced disease## Neuronal Types Affected### Pyramidal NeuronsCBD cortical tau pathology has a distinct laminar signature[^4][^7]:- Layer V pyramidal neurons: Corticospinal, corticobulbar, and corticopontine projection neurons. These large pyramidal cells are the most vulnerable cortical population, showing dense NFTs, ballooned neurons, and progressive cell death- Layer III pyramidal neurons: Corticocortical association neurons connecting functionally related cortical areas. Their degeneration disrupts the cortical connectome, producing disconnection syndromes (e.g., alien limb from callosal disconnection)- Von Economo neurons (VENs): Spindle-shaped neurons in anterior cingulate and frontoinsular cortex; vulnerable in CBD, contributing to social cognition and interoceptive deficits[^8]### Cortical InterneuronsGABAergic interneuron vulnerability in CBD is variable but clinically significant:- Parvalbumin (PV) fast-spiking interneurons: Perisomatic basket cells that regulate pyramidal neuron output. PV interneuron loss reduces cortical inhibition, contributing to cortical myoclonus and hyperexcitability[^9]- Somatostatin (SST) interneurons: Dendrite-targeting Martinotti cells in layers II/III and V. SST neuron loss disrupts feedback inhibition and lateral inhibition circuits- VIP interneurons: Disinhibitory circuit elements that gate SST/PV interneuron activity. Their relative preservation may amplify the effects of PV/SST loss## Pathological Features### CBD-Specific Tau LesionsCBD produces a distinctive set of cortical tau inclusions[@dickson2002][^10]:- Astrocytic plaques: The defining pathological feature of CBD. Unlike the tufted astrocytes of PSP, CBD astrocytic plaques consist of tau-positive astrocytic processes arranged in a planar, disc-shaped configuration. They are concentrated in cortical layers II-III and are most abundant in perirolandic cortex- Ballooned achromatic neurons: Swollen cortical neurons with displacement of Nissl substance to the cell periphery and accumulation of phosphorylated neurofilaments. Most prominent in layers III and V of affected cortex[^11]- Corticobasal bodies: Dense, round tau inclusions in cortical neurons- Neuropil threads: Extremely dense tau-positive threads permeating the cortical neuropil — the most abundant tau lesion type in CBD by volume- Coiled bodies: Oligodendroglial tau in subcortical white matter beneath affected cortex### Tau BiochemistryCBD tau is exclusively composed of 4R isoforms (0N4R, 1N4R, 2N4R)[^12]:- Phosphorylation sites: Ser202/Thr205 (AT8), Thr231, Ser262 (12E8), Ser396/404 (PHF-1)- Cryo-EM structure: CBD tau filaments fold into a unique four-layered β-sheet structure distinct from the C-shaped fold of PSP tau and the PHF/SF folds of AD tau[^13]- Strain hypothesis: The distinct CBD and PSP tau conformations may explain why these two 4R tauopathies produce different regional vulnerability patterns (cortical in CBD vs subcortical in PSP)### Neurodegeneration Pattern- Asymmetric cortical atrophy: CBD characteristically produces unilateral or markedly asymmetric cortical thinning, most prominent in the perirolandic and posterior frontal regions contralateral to the more affected limbs[^14]- White matter degeneration: Severe myelin loss in subcortical U-fibres and long association tracts, producing cortical disconnection- Spongiform change: Superficial cortical neuropil vacuolation, particularly in layers II-III, reflecting synaptic loss and neuronal dropout## Molecular Mechanisms### Selective VulnerabilitySeveral factors determine why CBD preferentially affects cortical neurons[^7][^15]:1. MAPT H1 haplotype: Present in >90% of CBD patients; H1 increases 4R tau expression, preferentially affecting neurons with high baseline tau levels2. Layer V pyramidal neuron properties: Long axonal projections (up to 1 metre for corticospinal neurons) create enormous bioenergetic demand for axonal transport; tau dysfunction disrupts this transport early3. Cortical excitatory activity: High-frequency glutamatergic transmission exposes cortical neurons to excitotoxic vulnerability4. Asymmetric onset mechanism: Unknown, but may relate to stochastic initial tau seeding in one hemisphere, followed by prion-like propagation through corticocortical and corticothalamic projections### Tau Propagation in Cortical NetworksCBD tau spreads through functionally connected cortical circuits[^16]:- Corticocortical spread: Layer III pyramidal neurons connect cortical areas within the same hemisphere; tau propagation follows these association fibres- Callosal spread: Interhemispheric tau transfer via corpus callosum, potentially explaining the progressive involvement of the initially spared hemisphere- Corticostriatal spread: Cortical tau seeds the striatum via corticostriatal projections, producing the subcortical pathology seen in advanced CBD- Corticothalamic spread: Layer VI corticothalamic neurons transport tau to thalamic nuclei### NeuroinflammationCortical neuroinflammation amplifies degeneration[^10][^17]:- Microglial activation: Dense microglial clusters in affected cortical regions, with CD68-positive phagocytic phenotype- Astrocytic plaques: CBD astrocytic plaques are not merely bystander lesions — they represent active tau propagation in astrocytic networks and impair glutamate homeostasis, BBB function, and metabolic support- Complement activation: C1q and C3 deposition on cortical synapses tags them for microglial elimination (synaptic stripping)## Clinical Correlation### Motor FeaturesCortical neuron degeneration produces the characteristic motor phenotype of CBS[^3][^18]:- Limb apraxia: Inability to perform learned skilled movements despite intact motor strength and comprehension. Ideomotor apraxia (gesture execution) from parietal/premotor degeneration; ideational apraxia (multi-step action sequences) from broader cortical loss- Alien limb phenomenon: Involuntary, purposive-appearing movements of the affected limb, reflecting loss of cortical motor control with preserved subcortical motor circuits- Cortical myoclonus: Brief, stimulus-sensitive jerks arising from hyperexcitable cortex (loss of PV interneuron inhibition), with cortical correlate on EEG (giant somatosensory evoked potentials)- Dystonia: Limb dystonia contralateral to the more affected hemisphere### Sensory Features- Cortical sensory loss: Impaired two-point discrimination, graphaesthesia, and stereognosis reflecting posterior parietal degeneration- Sensory neglect: Hemisensory extinction to double simultaneous stimulation### Cognitive and Behavioural Features- Executive dysfunction: Impaired planning, set-shifting, and working memory from prefrontal involvement[^6]- Non-fluent aphasia: CBS with progressive non-fluent aphasia when the dominant hemisphere is more affected- Behavioural variant: Disinhibition, apathy, or compulsive behaviours when frontal cortex is predominantly affected## Biomarkers and Neuroimaging### Structural MRI- Asymmetric cortical atrophy: Perirolandic and posterior frontal cortex contralateral to the clinically affected side[^14]- Cortical thickness mapping: Automated measures show progressive thinning in motor and premotor cortex- White matter changes: Reduced fractional anisotropy in subcortical white matter on DTI### Molecular Imaging- Tau PET: ¹⁸F-flortaucipir binding in asymmetric cortical pattern, correlating with atrophy and clinical severity[^19]- FDG-PET: Asymmetric cortical hypometabolism, most prominent in perirolandic cortex- Amyloid PET: Negative (excluding AD pathology as the cause of CBS)## Therapeutic Implications### Symptomatic Management- Levodopa: Minimal benefit in CBS/CBD (typically <20% response rate)[^20]- Clonazepam: For cortical myoclonus (0.5-2 mg/day)- Botulinum toxin: For focal dystonia- Occupational therapy: Adaptive strategies for apraxia and ADL limitations- Speech-language therapy: For progressive aphasia and dysphagia### Disease-Modifying Approaches- Anti-tau immunotherapy: Targeting extracellular tau to block corticocortical spread- Tau ASOs: MAPT mRNA reduction to decrease 4R tau production in vulnerable cortical neurons- Autophagy enhancers: Rapamycin, lithium — clearing intracellular tau aggregates- Kinase inhibitors: Targeting GSK-3β and CDK5 to reduce tau hyperphosphorylation### PSP/CBD OverlapCBD and PSP share 4R tau pathology but differ in regional emphasis. Some patients present with CBS clinically but have PSP pathology at autopsy, and vice versa[^2]. Key differentiators include:- Astrocytic plaques (CBD) vs tufted astrocytes (PSP)- Cortical emphasis (CBD) vs subcortical/brainstem emphasis (PSP)- Asymmetric (CBD) vs symmetric (PSP) clinical presentation## Cross-References- Corticobasal Degeneration — Disease overview- Corticobasal Syndrome — Clinical phenotype- Progressive Supranuclear Palsy — Sister 4R tauopathy- Cortical Pyramidal Neurons in CBD- Globus Pallidus in CBD- Substantia Nigra in CBD- 4R Tauopathy Mechanisms- Tau Hyperphosphorylation## Related Pages## Related Pages### Neurodegenerative Diseases- Alzheimer's Disease- Parkinson's Disease- Progressive Supranuclear Palsy (PSP)- Corticobasal Syndrome (CBS)- Corticobasal Degeneration (CBD)### Mechanisms & Pathways- Tauopathy- 4R Tauopathy Molecular Mechanisms### Treatments- CBS/PSP Treatment Rankings- CBS/PSP Daily Action Plan### Cell Types- Progressive Supranuclear Palsy Neurons- Corticobasal Syndrome Neurons## Related NeuroWiki Pages### Disease Pages- Corticobasal Degeneration — CBD overview- Progressive Supranuclear Palsy — Related tauopathy- CBD Genetic Variants — Genetic factors- Primary Age-Related Tauopathy — Related tauopathy- Alzheimer's Disease — Disease comorbidity- Parkinson's Disease — Lewy body disease- FTLD-Tau — Tauopathy spectrum### Gene & Protein Pages- MAPT Gene — Major risk gene- MAPT Protein — Tau protein- Tau Protein — 4R tau isoforms- DCTN1 Gene — Dynactin### Cell Type Pages- Cortical Neurons — Affected neurons- Basal Ganglia Neurons — Motor pathways- Substantia Nigra — Dopamine neurons- Globus Pallidus — Basal ganglia output### Mechanism Pages- Tauopathy — Tau pathology mechanisms- Neuroinflammation — Glial activation- Axonal Transport — Transport defects### Treatment Pages- CBD Treatment — Treatment options- CBD/PSP Daily Action Plan — Management- Clinical Trials — Trial information### Biomarker Pages- Tau PET — Imaging biomarker- MRI Patterns — Structural imaging- DTI Imaging — White matter changes describes a neural cell population with specific vulnerability or functional significance in neurodegenerative disease. This page covers cell morphology, molecular markers, connectivity, and disease-specific pathological changes.
<!-- multi-taxonomy-enrichment -->
This page is part of the CBS/PSP evidence graph. Related pages:
dickson2002, Office of Rare Diseases neuropathologic criteria for corticobasal degeneration (2002)